MarketsandMarkets

Biomarker and Companion Diagnostics Conference - EU Edition

5th - 6th October 2023

The Westin Grand Frankfurt, Germany

Discovering the latest technologies and biomarkers that drive translational research and precision medicine.

MarketsandMarkets brings to you the Biomarker and Companion Diagnostics Conference scheduled to be held on 5th-6th October 2023 at The Westin Grand Frankfurt, Germany. This event is designed to provide forward-looking insights into the latest trends and tools impacting biomarker research, it brings together leading experts from global pharmaceutical organisations, innovative biotech companies and internationally renowned academic institutions working across multiple therapeutic areas and stages of drug development.

This conference unites advances in biomarker use for drug discovery and development, alongside biomarkers for cancer. The Expert Panel will take you through their presentations which will include problems, solutions and services in the Clinical Applications of Biomarkers in Immuno-Oncology, Neurology and Inflammatory Diseases. Attendees would evidence the examples and the case studies which will help in creating the revenue. The keynote presentations would also help the attendees understand the issues related to clinical translation of biomarkers.

WHAT TO EXPECT

  • Commercialization of CDx
  • Proteomics and Genomics based Biomarkers.
  • Biomarker Drug Discovery and Assay Development
  • Multiplex Companion Diagnostics and Regulatory Guidelines
  • Design of clinical trials in CDx
  • Digital Biomarkers, Predictive Biomarkers, Precision Medicine, and Big Data
  • Clinical Applications of Biomarkers in Immuno-Oncology, Neurology, and Inflammatory Diseases

  • Hear from and meet with the key industry and academic innovators in biomarkers, translational medicine, clinical development, and diagnostics.
  • Discover the latest integration of biomarkers in early drug development through case studies by major pharma on multiple therapeutic areas, including immuno-oncology, neuroscience, cardiology, immunology respiratory rare diseases, and cell and gene therapies.
  • Gain novel insights into key biomarkers for detection, monitoring, and diagnosis, including innovative applications of digital markers.
  • Benefit from case studies on topical technology innovation within digital pathology, AI & imaging, flow cytometry, multiplexing, mass spectrometry and spatial biology tools.
  • Unparalleled networking opportunities. The two-day congress offers an interactive platform for high-level scientific and business discussions. Participate in formal or informal discussions during our networking breaks and pre-organised 1-2-1 meetings.

Researchers, scientists, clinicians, academicians and professionals from pharmaceutical companies, Bio-pharma companies & Universities and Research institutes working in:

  • Biomarker discovery/development
  • Translational research
  • Clinical Biomarker
  • Biomarkers in IO and Neurological disorders
  • Imaging Biomarkers
  • Pathology
  • Companion Diagnostics
  • Biomarker Imaging
  • Proteomics Biomarkers
  • Experimental Medicine
  • Data Science
  • Biomarkers in Clinical Discovery
  • Immuno-oncology/Neuroscience Drug Discovery
  • Diagnostic Biomarkers development
  • Personalized Medicine
  • Immunology Biomarkers

CONFERENCE AGENDA

Registration

08:15 - 08:50

Welcome note from MarketsandMarkets

08:50 - 08:55

Opening remarks from the Chairman

Allan Stensballe

Allan Stensballe, Associate Professor, Aalborg University

08:55 - 09:00

CLINICAL BIOMARKER DRUG DEVELOPMENT AND PRECISION MEDICINE

Aligning Innovation with Precision Medicine

Elizabeth Sheppard

Elizabeth Sheppard, Global Pricing & Market Access Director, Oncology Diagnostics,, AstraZeneca

09:00 - 09:35

Gene expression signatures: key success factors

Eike Staub

Eike Staub, Head of Oncology Data Science, Merck Healthcare, Germany

09:35 - 10:10

Transforming Oncology with Predicine’s Liquid Biopsy Solutions

Shidong Jia

Shidong Jia, Founder, CEO, Predicine

10:10 - 10:45

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:45 - 11:30

DNA Methylation: Potential Surrogate Endpoint Biomarkers in Drug Development and Clinical Trails

11:30 - 12:05

Anti-CD89 antibody for personalized treatment of IgA-mediated inflammatory disorders: Autoantigen-specific IgA, a biomarker with strong effector functions

Louis Boon

Louis Boon, CSO and Board Member, JJP Biologics

12:05 - 12:40

Precision Proteomic Landscape of health-to-disease transitions of Rheumatic Musculoskeletal disorders and links to Cancer associate irAEs

Allan Stensballe

Allan Stensballe, Associate Professor, Aalborg University

12:40 - 13:15

Lunch and Poster Presentation | One-to-One Networking Meeting

13:15 - 14:15

Why do 95% of oncology drugs fail in clinical development, and how can biomarkers help?

Philip Beer

Philip Beer, Chief Scientific Officer, Step Pharma

14:15 - 14:50

Enhanced Biomarker Discovery and Validation Using TMT® Proteomics

Illip Burmester

Illip Burmester, Technical and Applications Manager, Proteome Sciences

14:50 - 15:25

When over 99% of published Biomarkers end up in the bin what can we do to reduce this waste and pick out the ones that could be rescued?

Christopher Peters

Christopher Peters, Clinical Senior Lecturer, Imperial College London

15:25 - 00:00

Evening Refreshments and Poster Presentation | One-to-One Networking Meetings

16:00 - 16:45

Panel Discussion: Clinical biomarker development is critical to bring precision medicine from a scientific concept into clinical practice-Views?

Louis Boon

Louis Boon, CSO and Board Member, JJP Biologics

Elizabeth Sheppard

Elizabeth Sheppard, Global Pricing & Market Access Director, Oncology Diagnostics,, AstraZeneca

Vaios Karanikas

Vaios Karanikas, Biomarker Experimental Medicine Leader, Oncology, Roche

Aparna Duggirala

Aparna Duggirala, Lecturer, Clinical Genetics, University of Derby

Christopher Peters

Christopher Peters, Clinical Senior Lecturer, Imperial College London

16:45 - 00:00

Closing Remarks from the Chairperson

17:20 - 17:20

Drinks Reception & Networking

17:20 - 17:20

End of Day 1

17:20 - 17:20

Registration

08:15 - 08:50

Welcome note from MarketsandMarkets

08:50 - 08:55

Opening Remarks from the Chairperson

Pier Francesco Ferrucci

Pier Francesco Ferrucci, NIBIT President, Oncology Department Director, Multimedica Group

08:55 - 09:00

CDX DEVELOPMENT, INTEGRATION AND COMMERCIALIZATION: CLINICAL APPLICATIONS OF CDX

Biomarkers for neurological diseases and it’s challenges

David Brassat

David Brassat, Global Biomarker Lead, Novartis

09:00 - 09:35

Point-of-Care quantitative lateral flow diagnostic tests

Aart van Amerongen

Aart van Amerongen, Senior scientist BioSensing & Diagnostics (BSD) , Wageningen UR

09:35 - 10:10

Next generation technologies in metabolic disease diagnosis and therapeutic effectiveness

Aparna Duggirala

Aparna Duggirala, Lecturer, Clinical Genetics, University of Derby

10:10 - 10:45

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:45 - 11:30

Precision medicine in rare diseases – learnings and opportunities

Thomas Hach

Thomas Hach, Executive Director Patient Engagement, Cardiovascular, Renal & Metabolism Patient Engagement, Novartis

11:30 - 12:05

Challenges of measuring novel biomarkers using plate-based methods in large clinical studies

Daniel Chapman

Daniel Chapman, Post Doctoral Research Fellow, University of Oxford

12:05 - 12:40

Single-Cell Sequencing in Rare Diseases and our Research is now more focusing on Therapeutics of Rare Diseases: Using Autologous Stem Cell Therapy in the Area of Muscle Diseases and Cancer.

Rick Kamps

Rick Kamps, NGS Manager, Maastricht University

12:40 - 13:15

Closing Remarks from the Chairperson

13:15 - 13:20

Lunch and Poster Presentation | One-to-One Networking Meetings

13:20 - 13:20

End of the conference

13:20 - 13:20

SPEAKERS

Illip Burmester

Illip Burmester

Technical and Applications Manager, Proteome Sciences

Vaios Karanikas

Vaios Karanikas

Biomarker Experimental Medicine Leader, Oncology, Roche

Louis Boon

Louis Boon

CSO and Board Member, JJP Biologics

Aart van Amerongen

Aart van Amerongen

Senior scientist BioSensing & Diagnostics (BSD) , Wageningen UR

Allan Stensballe

Allan Stensballe

Associate Professor, Aalborg University

Shidong Jia

Shidong Jia

Founder, CEO, Predicine

Christopher Peters

Christopher Peters

Clinical Senior Lecturer, Imperial College London

David Brassat

David Brassat

Global Biomarker Lead, Novartis

Eike Staub

Eike Staub

Head of Oncology Data Science, Merck Healthcare, Germany

Daniel Chapman

Daniel Chapman

Post Doctoral Research Fellow, University of Oxford

Aparna Duggirala

Aparna Duggirala

Lecturer, Clinical Genetics, University of Derby

Philip Beer

Philip Beer

Chief Scientific Officer, Step Pharma

Thomas Hach

Thomas Hach

Executive Director Patient Engagement, Cardiovascular, Renal & Metabolism Patient Engagement, Novartis

Elizabeth Sheppard

Elizabeth Sheppard

Global Pricing & Market Access Director, Oncology Diagnostics,, AstraZeneca

ENQUIRE NOW

SPONSORS

PARTNERS

LOCATION

Venue

The Westin Grand Frankfurt, Germany

PAST EVENT GALLERY